Opko Health Gets a Hold Rating from Jefferies

By Ryan Adsit

Jefferies analyst Eun Yang reiterated a Hold rating on Opko Health (NYSE: OPK) today and set a price target of $8. The company’s shares closed last Friday at $6.38, close to its 52-week low of $5.99.

According to TipRanks.com, Yang is a 3-star analyst with an average return of 0.8% and a 45.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Opko Health has an analyst consensus of Moderate Buy, with a price target consensus of $17.50.

The company has a one year high of $12.15 and a one year low of $5.99. Currently, Opko Health has an average volume of 4.29M.

Based on the recent corporate insider activity of 172 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year. Earlier this month, Richard Pfenniger, a Director at OPK bought 20,000 shares for a total of $68,600.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OPKO Health, Inc. is a diversified healthcare company. It operates through Diagnostics, and Pharmaceutical segments. The Diagnostics segment is consists of the pharmaceutical operates that the company acquired in Chile, Mexico, Ireland, Israel, and Spain and its pharmaceutical research and development operations. The Diagnostics segment is primarily comprised of the clinical and laboratory operations tit acquired through the acquisition of Bio-Reference and OPKO Lab and its point-of-care operations. The company was founded in October 1991 and is headquartered in Miami, FL.